OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
Pratia Inc has claimed 40% shares in KFGN, with an overall investment plan that assumes increased shareholding up to a clear majority position in the upcoming years. Dr. Ole Dammann will continue his leadership as CEO of KFGN. Additionally, as a Board Member of Pratia, he will support international growth of Site Network.
For more information, click here.